Table 1.
The clinicopathological characteristics of the enrolled patients.
| Patients (n) | Percentage (%) | |
|---|---|---|
| Age | ||
| <40 | 19 | 18.1% |
| ≥40 to <60 | 80 | 76.2% |
| ≥60 | 6 | 5.7% |
| Menstrual status | ||
| Premenopausal | 57 | 54.3% |
| Menopause | 48 | 45.7% |
| HR status | ||
| Positive | 65 | 61.9% |
| Negative | 40 | 38.1% |
| HER2 status | ||
| Positive | 57 | 54.3% |
| Negative | 48 | 45.7% |
| TNM staging | ||
| II-III | 6 | 5.7% |
| IV | 99 | 94.3% |
| Position of metastatic site | ||
| Nonvisceral | 38 | 36.2% |
| Visceral | 67 | 63.8% |
| Detection times | ||
| Once | 74 | 70.5% |
| Twice or more | 31 | 29.5% |
| Treatment mode | ||
| Neoadjuvant chemotherapy | 5 | 4.8% |
| Adjuvant chemotherapy | 1 | 1.0% |
| Palliative chemotherapy | 99 | 94.2% |
HR: hormone receptor; HER2: human epidermal growth factor receptor 2.